BridgeBio Pharma (BBIO) Accumulated Expenses (2018 - 2026)

BridgeBio Pharma has reported Accumulated Expenses for 9 years, with the latest figure at $39.3 million in Q1 2026.

• Quarterly Accumulated Expenses rose 17.61% year-over-year to $39.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.3 million (up 17.61% YoY) and the FY2025 annual result came in at $76.7 million, up 31.5% from the prior year.
• Accumulated Expenses eased to $39.3 million in Q1 2026 per BBIO's latest filing, from $76.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $76.7 million in Q4 2025 and troughed at $3.9 million in Q1 2024.
• A 5-year average of $33.3 million and a median of $32.6 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses plunged 79.51% in 2024, then surged 765.16% in 2025.
• Over 5 years, Accumulated Expenses stood at $17.5 million in 2022, then soared by 227.83% to $57.4 million in 2023, then climbed by 1.67% to $58.3 million in 2024, then jumped by 31.5% to $76.7 million in 2025, then plunged by 48.71% to $39.3 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $39.3 million, $76.7 million, and $56.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.